Alphamab Oncology (9966.HK) Comparison with companies in other sectors?

Alphamab Oncology has a share price of 962.19M. You can analyze Alphamab Oncology (9966.HK) competitors across different market sectors through stock heatmaps.

What are 9966.HK's NET and operating margins?

Alphamab Oncology (9966.HK) operating margin is around 0.16, and net profit margin is approximately 0.26 as of the latest reports.

In what way does 9966.HK's earnings per share (EPS) trend reflect its financial momentum?

Alphamab Oncology (9966.HK) EPS is 0.19 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Alphamab Oncology is 43.68, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Alphamab Oncology?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Alphamab Oncology like P/E which is 45.04, P/B which is 4.09, and PEG which is 0.28. Compare them with sector averages to evaluate if the stock is priced fairly.

Alphamab Oncology

9966.HK•HKSE

Healthcare

Biotechnology

HK$8.03

HK$0.00(0.00%)

Fundamental Analysis of Alphamab Oncology (9966.HK)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.19

P/E Ratio

43.68

ROE

0.10%

Net Margin

0.26%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$7.99B

Shares OutstandingTotal number of shares issued

$962.19M

Book Value/ShareNet worth per share

$1.86

Revenue/ShareAnnual revenue per share

$0.65

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.19

Net MarginNet income as percentage of revenue

25.99%

Operating MarginOperating income as percentage of revenue

15.78%

ROEReturn on shareholders' equity

9.61%

ROAReturn on total assets

7.42%

ROCEReturn on capital employed

5.08%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.05

Cash/ShareCash and equivalents per share

$1.59

FCF YieldFree cash flow as percentage of market cap

-0.70%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 9966.HKFinancial Ratios Analysis details for 9966.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 9966.HKSector Benchmarking details for 9966.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Alphamab Oncology Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Alphamab Oncology. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Alphamab Oncology's unique business strengths and challenges.

Key Financial Metrics for Alphamab Oncology

For Alphamab Oncology, essential financial indicators include EPS 0.19, PE 43.68, and ROE 0.10. These key ratios reveal insights into Alphamab Oncology's profitability, valuation, and operational health. Understanding these metrics enables you to compare Alphamab Oncology with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Alphamab Oncology

Metrics like Net Margin 25.99% and ROA 7.42% shed light on how well Alphamab Oncology is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Alphamab Oncology can sustain its operations and continue growing in the future.

Valuation and Market Position of Alphamab Oncology

Using ratios such as P/B Ratio 4.09 and PEG Ratio 0.28, investors can assess whether Alphamab Oncology is appropriately valued based on its financials and growth potential. These figures, combined with Alphamab Oncology's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Alphamab Oncology

Financial health indicators, such as Debt/Equity Ratio 0.10 and Cash Flow $-0.05, provide a snapshot of Alphamab Oncology's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Alphamab Oncology, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Alphamab Oncology

Investing in Alphamab Oncology based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Alphamab Oncology focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;